相似文献
1
Novel PARP7 Inhibitors for Treating Cancer.用于治疗癌症的新型聚（ADP-核糖）聚合酶7抑制剂
ACS Med Chem Lett. 2025 Mar 20;16(4):526-527. doi: 10.1021/acsmedchemlett.5c00127. eCollection 2025 Apr 10.
2
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
3
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.用于治疗癌症和免疫疾病的MALT1抑制剂
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
4
Novel MALT1 Inhibitors for Treating Cancer.用于治疗癌症的新型MALT1抑制剂
ACS Med Chem Lett. 2025 May 5;16(6):925-926. doi: 10.1021/acsmedchemlett.5c00229. eCollection 2025 Jun 12.
5
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
6
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
7
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
8
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.新型哌啶基吡啶基甲腈衍生物作为治疗癌症的QPCT和QPCTL抑制剂
ACS Med Chem Lett. 2025 Apr 14;16(5):758-759. doi: 10.1021/acsmedchemlett.5c00198. eCollection 2025 May 8.
9
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.新型哌啶基吡啶基甲腈衍生物作为治疗癌症的QPCT和QPCTL抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(4):540-541. doi: 10.1021/acsmedchemlett.5c00142. eCollection 2025 Apr 10.
10
Novel Spirocyclic WRN Helicase Inhibitors for Treating Cancer.用于治疗癌症的新型螺环WRN解旋酶抑制剂
ACS Med Chem Lett. 2025 Apr 25;16(5):764-765. doi: 10.1021/acsmedchemlett.5c00216. eCollection 2025 May 8.
本文引用的文献
1
Parps in immune response: Potential targets for cancer immunotherapy.聚（ADP-核糖）聚合酶在免疫反应中的作用：癌症免疫治疗的潜在靶点
Biochem Pharmacol. 2025 Apr;234:116803. doi: 10.1016/j.bcp.2025.116803. Epub 2025 Feb 16.
2
PARPs and ADP-ribosylation-mediated biomolecular condensates: determinants, dynamics, and disease implications.聚（ADP-核糖）聚合酶与ADP-核糖基化介导的生物分子凝聚物：决定因素、动力学及疾病影响
Trends Biochem Sci. 2025 Mar;50(3):224-241. doi: 10.1016/j.tibs.2024.12.013. Epub 2025 Feb 7.
3
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy.用于癌症治疗的表观遗传/细胞毒性双靶点抑制剂概述。
Eur J Med Chem. 2025 Mar 5;285:117235. doi: 10.1016/j.ejmech.2024.117235. Epub 2025 Jan 3.
4
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design.聚（ADP-核糖）聚合酶（PARP）抑制剂作为抗肿瘤药物的潜力及分子设计前景
J Med Chem. 2025 Jan 9;68(1):18-48. doi: 10.1021/acs.jmedchem.4c02642. Epub 2024 Dec 26.
5
Novel PARP7 Inhibitors for Treating Cancer.用于治疗癌症的新型聚（ADP-核糖）聚合酶7抑制剂
ACS Med Chem Lett. 2023 Nov 4;14(12):1615-1616. doi: 10.1021/acsmedchemlett.3c00458. eCollection 2023 Dec 14.
Zotero 插件